AbCellera Biologics Inc.
ABCL
$3.73
$0.092.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.34% | -8.07% | -14.28% | -11.24% | -36.13% |
| Total Depreciation and Amortization | -96.96% | -44.78% | 112.30% | 110.39% | 220.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,579.41% | 78.03% | -80.16% | -74.07% | -95.84% |
| Change in Net Operating Assets | 75.66% | 110.72% | 26.67% | -295.41% | -196.39% |
| Cash from Operations | 12.99% | 11.54% | -88.82% | -147.41% | -1,908.11% |
| Capital Expenditure | 37.10% | 26.41% | 24.63% | -1.88% | -3.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.10% | -40.54% | 269.16% | 238.60% | 199.70% |
| Cash from Investing | -21.29% | -65.42% | 339.09% | 154.91% | 128.70% |
| Total Debt Issued | 76.69% | 19.73% | 24.67% | 30.09% | 105.66% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -46.30% | -46.30% | -46.30% | -46.30% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,177.75% | -1,174.56% | -53.29% | 40.92% | 29.74% |
| Cash from Financing | 13.86% | -37.76% | 16.58% | 23.30% | 78.56% |
| Foreign Exchange rate Adjustments | -321.44% | 46.03% | -6,033.33% | -544.31% | 631.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.02% | -77.75% | 151.40% | 109.06% | 77.15% |